Quote:C'mon folks, just do some DD of your own. You know, part of DD is understanding rules for issuers. There is absolutely nothing as absurd as a requirement to file a disclosure that a 3(a)(10) transaction has been completed. Just like there is NO requirement to file a disclosure that a toxic lender has started OR completed converting OR selling shares.
There are MANY requirements for disclosure to cover all of the possible ways that ISSUERS can SELL shares. NONE for disclosing that issuers or anyone else is DONE issuing or selling shares. For example, SEC-reporting issuers are required to file an 8K to disclose when they issue a convertible note - BECAUSE they are, in effect, issuing stock, should the note convert. Yes, the stock is not officially ISSUED at that time, but when the noted is funded (money actually chages hands), that is the time that the clock starts on the 6-month restriction for Rule 144 exempt shares being "issued". The point is to force these issuers to report to shareholders that the 6-month clock is starting to tick for shares that, if converted, though currently restricted, could become unrestricted and free-trading, should the note holder convert.
And NO, a holder of 3(a)(10) exempt shares of ONCI is NOT holding OR selling shares now. Quite simply, that's NOT how it works. They get a tranche of shares and sell them, and then they get another and sell them, and so on, until the net proceeds from sales of shares satisfies the debt that is being paid through the 3(a)(10) process. This process CANNOT be completed until the shares are actually sold and the balance on the 3(a)(10) settlement is paid in full. So IF there is any statement from the company that the 3(a)(10) is done... it is DONE - shares given to seller (NB), shares SOLD in the market, total proceeds from sale of stock = total settlement amount for the 3(a)(10) transaction... DONE, DONE, DONE - no more 3(a)(10) shares to sell... ZERO... ZIP... NADA. Easy enough to understand?!?
Any issuer MAY freely disclose, in an 8K, in a press release, or a tweet, that a 3(a)(10) transaction has been completed. There is NO requirement to do so.
SB indicated in the previous Shareholder Letter that the 3(a)(10) was 99.9% complete, and he estimated completion by "today or tomorrow". He then tweeted a few days later that "...the 3(a)(10) is done... and there is NOT another 3(a)(10)." Easy enough to understand?!?
I am most definitely NOT the only shareholder that understands this process. Undoubtedly, there are many who could have offered this clarification, if it suited their interests. The mere fact that no one has clarified this should tell anyone paying attention here that there are some number of traders who see it in their best interest to let the FUD (fear, uncertainty and doubt) persist. Gee... could it be that there are more than a few flippers out there? And quite likely, more than a few longs who are not too upset to have more shares at a discount price. But look at the volume, accumulation and share price. Should tell you something - like... just do your DD.
I don't really care a whole helluva a lot, I've been absorbing more than my fair share of stock again over the past week+. Maybe I'm just concerned about losing self-respect, bottom-feeding like this to my heart's content from these low-volume capitulators, feeding on this FUD - all while I read numerous posts from seemingly unknowing traders who actually give credence to these ridiculous ideas that "well, maybe there's something to this claim that there are 3(a)(10) shares still converting." It's pretty simple. Flippers love FUD. But then again, so do longs. As I've already admitted, I have benefited from it.
Here is a good post for the other site by MFN about the
Top 10 Most Recent News Articles
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus
A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...
Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
Fluence Investors Face a November 27 Litigation Clock
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally
A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...
Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors
Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...
Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire
A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...
Continue ReadingTop 5 Most Recently Viewed Articles
Coca-Cola's Emerging Markets Strategy Fuels Long-Term Growth
Coca-Cola's Position in Emerging Markets Coca-Cola Co (NYSE: KO) stands as a beacon of growth, with a visionary strategy that highlights both immediate and long-term opportunities. The company has successfully positioned itself in vital markets, particularly in North America and Latin America, which have proven central to its success. According to recent insights from...
Continue Reading
Voda IQ Appoints Armando Piccinini to Drive European Sales
Voda IQ dropped some big news back in 2024 when they appointed Armando Piccinini as their European Sales Director. This guy’s got over twenty years under his belt in aquatic conservation, which they clearly hope will ramp up their sales strategy across Europe. But you gotta wonder—are the numbers behind this move really there? Can Experience Translate to Sales Growth?...
Continue Reading
Magnera Corporation to Shine at Upcoming Finance Conference
Magnera Corporation's Conference Participation Announcement Magnera Corporation (NYSE: MAGN) has made an exciting announcement regarding its upcoming participation in a significant financial event. The company is set to be a part of the 2025 Bank of America Leveraged Finance Conference, aimed at fostering connections with top institutional investors. The event will take...
Continue Reading
Bullish Momentum Unveiled: Insights on Merck & Co Stocks
Exciting Developments in Merck & Co Options Activity Notable investors are expressing strong optimism about Merck & Co. A recent analysis of options trading strategies reveals a wave of activity among traders aiming to capitalize on this potential. Options Trading Overview When reviewing the options history for Merck & Co (NYSE: MRK), we found a total of 33 trades that...
Continue Reading
Gilead Snags Arcellx: A High-Stakes Cancer Gamble Unfolds
The Big Play for Cancer Innovation Gilead Sciences Inc. (NASDAQ:GILD) pulled the trigger on a pretty huge acquisition deal, landing Arcellx Inc. (NASDAQ:ACLX) this past Monday for a staggering $115 per share, which gets better with a potential extra $5 per share on a contingent value right. That rings in a hefty total of $7.8 billion—no pocket change, folks. What’s...
Continue Reading